Cannabis Law Report

JULY 28, 2021

This includes First Time in Human (“FTiH”) clinical trials, which are expected to commence in 2022, for the Group’s lead compound OCT461201, a selective cannabinoid receptor type 2 (“CB2”) agonist with initial indications in the areas of post herpetic neuralgia and visceral pain caused by irritable bowel syndrome.

Cannabinoids 105

Cannabinoids Clinical Trials Safety Medicine 105

Project CBD

FEBRUARY 28, 2023

Despite the companies’ submitting the required data demonstrating the “reasonable expectation of safety under the recommended conditions of use,” the FDA rejected the applications, citing the drug preclusion clause. Available at: [link] Accessed October 17, 2022. Accessed October 17, 2022. February 2, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. June 14, 2022 02:00 AM Eastern Daylight Time. However, we need rigorous clinical trials to ensure that this promise is realised.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

The Cannigma

FEBRUARY 1, 2023

To date, very few human clinical trials have been conducted to assess the effectiveness of THC or CBD in treating cancer. While RSO has been subject to increased popularity in treating certain types of cancers, no clinical trials have tested the safety or efficacy of RSO in humans, meaning that all evidence is anecdotal.

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. April 5, 2022.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

APRIL 13, 2022

Apr 12, 2022, 07:00 ET. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Transaction expected to close in June 2022 , following anticipated shareholder approval. Numinus Wellness Inc. .

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

JANUARY 12, 2022

Through the partnership, Maya’s Real World Evidence Platform will be one of the core services offered to the association’s members when it officially launches in Q4 of 2022. We don’t believe safety and access are opposing polarities that must be constantly balanced.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

SEPTEMBER 12, 2022

08, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has completed what it believes to be the largest legal natural psilocybin harvest in Canadian history. VANCOUVER, British Columbia, Sept. Penis Envy. Blue Pulaski.

History 52

History Clinical Trials Legalization Research and Development 52

Cannabis Law Report

DECEMBER 26, 2021

Along with the previously completed in vitro assays, these studies serve as the benchmark for further preclinical work in 2022 and will contribute to regulatory submissions as the company advances its DMT program. EBRX-101 on Track to Submit Regulatory Package for Human DMT Clinical Trial. About Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

MAY 29, 2022

To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision. Clinical Trials and Human Subject Protections. 1, 2022), [link]. [14] 2] David E.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Chapman continued.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 23, 2022

The continued criminalization of all drugs and the people who use them increases harms to public health and safety. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. September 1, 2022.

Decriminalization 52

Decriminalization Advocacy Research and Development Education 52

Cannabis Law Report

DECEMBER 7, 2021

A full report of the anonymized, aggregate findings will be released in early 2022. Initial findings indicate a significant number of participants experienced clinically meaningful improvements, meaning they realized distinct and palpable improvements in quality of life through improvements in the respective health outcomes studied.

Clinical Trials 52

Clinical Trials CBD Data Sleep 52

Cannabis Law Report

OCTOBER 9, 2021

Under HB 1959 , which was formally filed with 19 cosponsors on Wednesday, the state Department of Health would authorize at least two entities to “plant, grow and cultivate natural psilocybin mushroom product solely for use in the clinical studies of psilocybin.”. Session of 2021 – 2022 Regular Session. House of Representatives.

Therapy 52

Therapy Clinical Trials Treatment Legislation 52

Cannabis Law Report

DECEMBER 28, 2021

We recently announced that we anticipate commencing our initial human trial for Epoladerm™ in the second quarter of 2022. We are on track to add accomplishments in 2022 and I remain confident that we have the significant financial strength to continue advancing our pipeline,” concluded Mr. Mack.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

JULY 21, 2022

JULY 21, 2022. The comprehensive legislation would end federal cannabis prohibition by removing cannabis from the Controlled Substances Act; empower states to create their own cannabis laws; ensure federal regulation protects public health and safety; and prioritize restorative and economic justice .

Safety 52

Safety Legislation Clinical Trials Banking 52

Cannabis Law Report

NOVEMBER 26, 2021

Corporate and Clinical Development Highlights Include: Completed Patient Enrollment in Phase III Psoriasis Study – The Phase III Comfort™ study completed patient enrollment. Topline results are expected in Q1 2022. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

Cannabis Law Report

FEBRUARY 28, 2022

20 February 2022. Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Essay by I. war on drugs. 15 × 15.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

OCTOBER 29, 2021

(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. The primary endpoint of this Phase 1 trial was safety and tolerability.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

DECEMBER 2, 2021

These recommendations will be sent to the Oregon Health Authority (OHA) for consideration during formal rulemaking, with hearings scheduled from February 14 to February 25, 2022. Safety, Ethics and Responsibilities of a Psilocybin Facilitator (10 Hours). Psilocybin Pharmacology, Neuroscience, and Clinical Research (12 Hours).

Law 52

Law Programs Therapy Education 52

The Cannigma

DECEMBER 12, 2022

Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. Current clinical trials are underway using a synthetic nasal spray of 5-MeO-DMT in patients with major depressive disorder. Iboga safety: Numerous concerns about the safety of iboga have been raised by scientists.

History 119

History Microdosing Research and Development Clinical Trials 119

Cannabis Law Report

MAY 1, 2022

Subsection 3(d) gives the agency power to require service center operators to meet public health and safety standards and industry best practices established by the agency. The addition of the word “including” suggests that public health and safety are two examples of the goals of sections 3 to 129 rather than an exhaustive list.

Safety 52

Safety History Programs Clinical Trials 52

The Cannigma

JANUARY 13, 2023

While migraines are a commonly reported condition by patients in cannabis studies, there is little clinical research on how cannabis can influence migraine pain. Russo concluded the evidence he examined “supports experimental protocols of cannabis usage in migraine treatment should go forward employing modern controlled clinical trials.”

Terpenes 132

Terpenes Strains THC Treatment 132

Veriheal

MAY 16, 2022

Following the successful experiment into the potential safety and efficacy of using ketamine for Parkinson’s patients, the university proceeded to sign an exclusive licensing partnership with Pharmather Inc. , At the current time, researchers are busy carrying out a small-scale Phase I clinical trial into ketamine for PD.

Research and Development 19

Research and Development Treatment Clinical Trials Patients 19